REPL RSI Chart
Last 7 days
0.5%
Last 30 days
-10.7%
Last 90 days
-16.7%
Trailing 12 Months
-67.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 1.9M | 0 | 0 | 0 |
2023 | 10.0M | 15.8M | 20.8M | 23.8M |
2022 | 1.7M | 1.3M | 1.7M | 4.3M |
2021 | 2.8M | 2.9M | 2.9M | 2.4M |
2020 | 3.1M | 3.1M | 3.3M | 2.9M |
2019 | 2.8M | 3.3M | 3.2M | 2.6M |
2018 | 2.3M | 2.1M | 2.1M | 3.0M |
2017 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | patel sushil | acquired | - | - | 83,335 | chief executive officer |
Apr 01, 2024 | sarchi christopher | acquired | - | - | 22,225 | chief commercial officer |
Apr 01, 2024 | schwendenman andrew | acquired | - | - | 17,775 | chief accounting officer |
Apr 01, 2024 | hill emily luisa | acquired | - | - | 26,665 | chief financial officer |
Apr 01, 2024 | xynos konstantinos | acquired | - | - | 26,665 | chief medical officer |
Nov 16, 2023 | xynos konstantinos | sold | -79,858 | 10.92 | -7,313 | chief medical officer |
Nov 16, 2023 | sarchi christopher | sold | -57,384 | 10.92 | -5,255 | chief commercial officer |
Sep 18, 2023 | hill emily luisa | acquired | - | - | 83,330 | chief financial officer |
Sep 12, 2023 | esposito pamela | sold | -6,000 | 20.00 | -300 | chief business officer |
Sep 12, 2023 | esposito pamela | acquired | 990 | 3.3 | 300 | chief business officer |
Which funds bought or sold REPL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | sold off | -100 | -4,215,000 | - | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -35.19 | -763,433 | 1,289,370 | -% |
May 16, 2024 | COMERICA BANK | added | 5,307 | 6,067 | 6,184 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -7.22 | -33,726 | 300,819 | -% |
May 15, 2024 | D. E. Shaw & Co., Inc. | added | 310 | 6,103,370 | 8,151,910 | 0.01% |
May 15, 2024 | MORGAN STANLEY | reduced | -40.32 | -15,806,700 | 21,683,500 | -% |
May 15, 2024 | Ghost Tree Capital, LLC | added | 62.5 | 1,938,500 | 5,310,500 | 1.47% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | reduced | -7.01 | -83,264 | 759,736 | 0.05% |
May 15, 2024 | Royal Bank of Canada | reduced | -79.82 | -131,000 | 32,000 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | added | 170 | 1,560,680 | 2,523,230 | 0.01% |
Unveiling Replimune Group Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Replimune Group Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Replimune Group Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -100.0% | - | 5,686,000 | 6,049,000 | 6,186,000 | 5,876,000 | 2,675,000 | 1,112,000 | 343,000 | 131,000 | 87,000 | 725,000 | 788,000 | 816,000 | 550,000 | 755,000 | 686,000 | 859,000 | 951,000 | 620,000 | 687,000 | 325,500 |
Operating Expenses | 3.9% | 58,755,000 | 56,540,000 | 63,831,000 | 55,648,000 | 52,995,000 | 41,630,000 | 41,579,000 | 40,876,000 | 31,988,000 | 29,698,000 | 29,247,000 | 27,381,000 | 22,184,000 | 20,275,000 | 19,663,000 | 17,833,000 | 16,385,000 | 16,664,000 | 12,242,000 | 10,907,000 | 7,826,000 |
S&GA Expenses | -100.0% | - | 13,693,000 | 14,730,000 | 15,211,000 | 15,041,000 | 11,369,000 | 12,745,000 | 11,398,000 | 10,252,000 | 10,345,000 | 9,345,000 | 8,827,000 | 5,959,000 | 5,953,000 | 5,613,000 | 5,676,000 | 5,197,000 | 4,716,000 | 4,074,000 | 3,450,000 | 2,410,500 |
R&D Expenses | -0.6% | 42,578,500 | 42,847,000 | 49,101,000 | 40,437,000 | 37,954,000 | 30,261,000 | 28,834,000 | 29,478,000 | 21,736,000 | 19,353,000 | 19,902,000 | 18,554,000 | 16,225,000 | 14,322,000 | 14,050,000 | 12,157,000 | 11,188,000 | 11,948,000 | 8,168,000 | 7,457,000 | 5,415,500 |
EBITDA Margin | -1196.2% | -110 | -8.51 | -9.22 | -11.08 | -16.95 | -26.90 | -69.16 | -90.04 | -66.95 | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -103.8% | -38,500 | 1,012,000 | 955,000 | 1,115,000 | 1,022,000 | 941,000 | - | - | - | - | - | - | 1,000 | 247,000 | 286,000 | 284,000 | - | 834,000 | 195,000 | - | - |
Income Taxes | -113.6% | -64,500 | 473,000 | -201,000 | 200,000 | 300,000 | - | - | - | -55,000 | 12,000 | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -8.9% | -55,140,000 | -50,647,000 | -60,245,000 | -49,354,000 | -48,951,000 | -39,690,000 | -43,102,000 | -42,253,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -1189.5% | -113 | -8.79 | -9.54 | -11.43 | -17.39 | -27.70 | -70.55 | -91.79 | -68.19 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -7.8% | -55,090,500 | -51,120,000 | -60,044,000 | -49,555,000 | -49,261,500 | -39,690,000 | -43,102,000 | -42,253,000 | -31,716,000 | -29,674,000 | -29,355,000 | -27,311,000 | -21,499,000 | -21,783,000 | -20,095,000 | -17,493,000 | -15,789,000 | -16,189,000 | -11,139,000 | -9,508,000 | -6,656,000 |
Net Income Margin | -1187.2% | -113 | -8.82 | -9.55 | -11.46 | -17.42 | -36.79 | -87.71 | -103 | -68.20 | -44.64 | -34.72 | -31.17 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 2.0% | -46,166,000 | -47,123,000 | -44,039,000 | -49,037,000 | -33,047,000 | -29,144,000 | -33,606,000 | -34,523,000 | -23,709,000 | -18,813,000 | -23,389,000 | -18,605,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -8.5% | 488 | 533 | 562 | 604 | 647 | 679 | 436 | 459 | 461 | 485 | 503 | 524 | 543 | 559 | 314 | 330 | 234 | 250 | 151 | 144 | 154 |
Current Assets | -9.5% | 434 | 479 | 508 | 550 | 593 | 624 | 379 | 402 | 404 | 428 | 444 | 465 | 484 | 499 | 252 | 268 | 174 | 191 | 118 | 128 | 141 |
Cash Equivalents | -22.0% | 76.00 | 98.00 | 76.00 | 106 | 147 | 208 | 91.00 | 114 | 108 | 134 | 162 | 194 | 184 | 326 | 45.00 | 106 | 61.00 | 63.00 | 65.00 | 40.00 | 27.00 |
Net PPE | 10.7% | 10.00 | 9.00 | 8.00 | 8.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 | 4.00 | 1.00 | 12.00 |
Liabilities | 1.6% | 113 | 111 | 97.00 | 90.00 | 91.00 | 83.00 | 52.00 | 49.00 | 50.00 | 48.00 | 46.00 | 45.00 | 44.00 | 43.00 | 53.00 | 52.00 | 50.00 | 53.00 | 31.00 | 13.00 | 16.00 |
Current Liabilities | 4.6% | 40.00 | 39.00 | 40.00 | 32.00 | 34.00 | 26.00 | 24.00 | 20.00 | 21.00 | 18.00 | 17.00 | 15.00 | 15.00 | 13.00 | 13.00 | 12.00 | 12.00 | 14.00 | 12.00 | 13.00 | 10.00 |
Long Term Debt | 0.8% | 45.00 | 44.00 | 29.00 | 29.00 | 29.00 | 28.00 | - | - | - | - | - | - | - | - | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | - | - |
LT Debt, Non Current | - | - | - | - | - | 29.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -11.2% | 375 | 422 | 465 | 514 | 555 | 595 | 384 | 410 | 411 | 438 | 457 | 479 | 499 | 516 | 261 | 278 | 184 | 198 | 121 | 130 | 138 |
Retained Earnings | -8.5% | -701 | -646 | -595 | -535 | -485 | -436 | -396 | -353 | -311 | -279 | -249 | -220 | -193 | -171 | -149 | -129 | -112 | -96.51 | -80.32 | -69.18 | -59.77 |
Additional Paid-In Capital | 0.7% | 1,071 | 1,063 | 1,055 | 1,045 | 1,035 | 1,028 | 778 | 763 | 723 | 717 | 707 | 700 | 692 | 688 | 412 | 409 | 297 | 295 | 202 | 200 | 199 |
Shares Outstanding | 0.0% | 61.00 | 61.00 | 59.00 | 59.00 | 57.00 | 56.00 | 54.00 | 54.00 | 47.00 | 52.00 | 52.00 | 52.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 606 | - | - | - | 487 | - | - | - | 620 | - | 500 | - | - | - | 178 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 2.0% | -46,166 | -47,123 | -43,590 | -48,588 | -32,796 | -28,589 | -33,210 | -33,455 | -22,557 | -18,348 | -22,961 | -18,314 | -16,128 | -12,992 | -17,179 | -15,090 | -11,262 | -15,735 | -19,973 | -13,582 | -6,033 |
Share Based Compensation | -3.8% | 7,924 | 8,240 | 9,115 | 8,846 | 6,922 | 7,023 | 6,992 | 7,194 | 5,773 | 5,918 | 6,313 | 6,250 | 3,472 | 3,049 | 2,801 | 2,468 | 1,806 | 2,344 | 1,781 | 1,810 | 907 |
Cashflow From Investing | -57.0% | 23,201 | 53,956 | 12,683 | 7,361 | -22,752 | -125,101 | 36.00 | 5,315 | -4,326 | -13,420 | -11,052 | 26,992 | -126,273 | 31,421 | -44,798 | -49,126 | 7,841 | -65,209 | 25,324 | 26,811 | 10,474 |
Cashflow From Financing | -100.9% | -130 | 14,870 | 438 | 1,105 | -77.00 | 271,435 | 7,423 | 32,522 | 359 | 3,969 | 1,150 | 1,120 | 785 | 262,198 | -35.00 | 109,514 | 34.00 | 90,364 | 9,750 | 18.00 | 41.00 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 174,963 | $ 126,527 |
Selling, general and administrative | 59,810 | 50,553 |
Total operating expenses | 234,773 | 177,080 |
Loss from operations | (234,773) | (177,080) |
Other income (expense): | ||
Research and development incentives | 1,920 | 2,914 |
Investment income | 23,356 | 10,006 |
Interest expense on finance lease liability | (2,163) | (2,197) |
Interest expense on debt obligations | (4,497) | (1,963) |
Other income (expense) | 771 | (5,676) |
Total other income, net | 19,387 | 3,084 |
Loss before income taxes | (215,386) | (173,996) |
Income tax provision | 408 | 288 |
Net loss | $ (215,794) | $ (174,284) |
Earnings Per Share, Basic | $ (3.24) | $ (2.99) |
Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ (3.24) | $ (2.99) |
Weighted average common shares outstanding, basic (in shares) | 66,569,894 | 58,213,010 |
Weighted average common shares outstanding, diluted (in shares) | 66,569,894 | 58,213,010 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Mar. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 74,457 | $ 146,590 |
Short-term investments | 346,211 | 436,796 |
Research and development incentives receivable | 4,922 | 2,939 |
Prepaid expenses and other current assets | 8,077 | 6,278 |
Total current assets | 433,667 | 592,603 |
Property, plant and equipment, net | 10,483 | 7,479 |
Restricted cash | 1,700 | 1,636 |
Right-to-use asset – operating leases | 4,635 | 5,208 |
Right-to-use asset – financing leases | 37,237 | 39,665 |
Total assets | 487,722 | 646,591 |
Current liabilities: | ||
Accounts payable | 2,578 | 5,364 |
Accrued expenses and other current liabilities | 33,981 | 24,704 |
Operating lease liabilities, current | 1,161 | 1,118 |
Financing lease liabilities, current | 2,718 | 2,639 |
Total current liabilities | 40,438 | 33,825 |
Operating lease liabilities, non-current | 3,771 | 4,389 |
Financing lease liabilities, non-current | 23,410 | 23,965 |
Long term debt, net of discount | 44,809 | 28,648 |
Other liabilities, non-current | 786 | 472 |
Total liabilities | 113,214 | 91,299 |
Commitments and contingencies (Note 13) | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2024 and March 31, 2023; 61,415,105 and 56,676,313 shares issued and outstanding as of March 31, 2024 and March 31, 2023, respectively | 61 | 57 |
Additional paid-in capital | 1,070,874 | 1,034,994 |
Accumulated deficit | (701,282) | (485,488) |
Accumulated other comprehensive income (loss) | 4,855 | 5,729 |
Total stockholders’ equity | 374,508 | 555,292 |
Total liabilities and stockholders’ equity | $ 487,722 | $ 646,591 |